Nonalcoholic Steatohepatitis Treatment Market – Insights
Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.
Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.
Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.
The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).
Global Nonalcoholic Steatohepatitis Treatment Market Dynamics
Source: Coherent Market Insights Analysis (2018)
Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the nonalcoholic steatohepatitis treatment market revenue
Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.
According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%.
Most therapies for NASH are in early- or mid-stage development and some are in late-stage studies. Multiple companies are focused on the development of drugs. In April 2018, AstraZeneca has licensed IONIS-AZ6-2.5-L, which has been renamed to AZD2693. The newly licensed drug is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis. In 2016 Bristol-Myers Squibb acquired rights for a NASH program from Osaka, Japan-based Nitto Denko Corporation.
Nonalcoholic Steatohepatitis Treatment Market Restraints
Despite the significant burden to the public health system, there are no FDA-approved specifically tailored drugs for nonalcoholic steatohepatitis treatment. Therefore, there is an immense need for effective treatment to manage the complex pathophysiologic processes of NASH. Numerous medications targeting different stages and molecular events in the disease process are currently in the pipeline, increasing the promise of successful treatment of NASH in the future.
Nonalcoholic Steatohepatitis Treatment Market - Regional Insights
On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.
According to the National Health and Nutrition Examination Survey, the proportion of NAFLD among chronic liver diseases increased from 47% to 75% between 1988 and 2008 in the U.S. According to the National Institutes of Health, in 2015 nearly 3 to 12% of adults in the U.S. were suffering from NASH. The major reason for this increase was an increase in metabolic risk factors. According to the Journal of Hepatology, in 2013, approximately one-third of adults exhibit a pattern of NAFLD in Europe.
Global Nonalcoholic Steatohepatitis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2018)
Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape
Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.
Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.
However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 26 market data tables and 28 figures on "Nonalcoholic Steatohepatitis Treatment Market” - Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.